Who
Steven H. Holtzman
Director
Company insider
Files Form 4 as: Director, CAMP4 Therapeutics; EVP Corporate Development, Biogen; Exec Chair of the Board of Dir, Infinity Pharmaceuticals; Director, Anadys Pharmaceuticals.
In numbers
- Trades disclosed
- 112
- Buys
- 2
- Sells
- 12
- Bought
- $209K
- Sold
- $8.3M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 2 Jun 2006
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | CAMP CAMP4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | CAMP CAMP4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
| 25 Jun 2025filed 27 Jun 2025 | CAMP CAMP4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 15 Oct 2024filed 15 Oct 2024 | CAMP CAMP4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —100,014 | filing |
| 15 Oct 2024filed 15 Oct 2024 | CAMP CAMP4 TherapeuticsBiotechnology | SEC FORM 4 Code C | —8,917 | filing |
| 23 Feb 2016filed 25 Feb 2016 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —579 at $0.00 | filing |
| 23 Feb 2016filed 25 Feb 2016 | BIIB BiogenBiotechnology | SEC FORM 4 Code F | $71K273 at $258.99 | filing |
| 23 Feb 2016filed 25 Feb 2016 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —579 at $0.00 | filing |
| 23 Feb 2016filed 25 Feb 2016 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code J | —1,149 at $0.00 | filing |
| 12 Feb 2016filed 17 Feb 2016 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —1,052 at $0.00 | filing |
| 12 Feb 2016filed 17 Feb 2016 | BIIB BiogenBiotechnology | SEC FORM 4 Code F | $122K495 at $247.22 | filing |
| 12 Feb 2016filed 17 Feb 2016 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —2,142 at $0.00 | filing |
| 12 Feb 2016filed 17 Feb 2016 | BIIB BiogenBiotechnology | SEC FORM 4 Code F | $202K819 at $247.22 | filing |
| 12 Feb 2016filed 17 Feb 2016 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,052 at $0.00 | filing |
| 12 Feb 2016filed 17 Feb 2016 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,142 at $0.00 | filing |
| 12 Feb 2016filed 17 Feb 2016 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code J | —1,394 at $0.00 | filing |
| 8 Feb 2016filed 9 Feb 2016 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —2,709 at $0.00 | filing |
| 8 Feb 2016filed 9 Feb 2016 | BIIB BiogenBiotechnology | SEC FORM 4 Code F | $223K890 at $250.77 | filing |
| 8 Feb 2016filed 9 Feb 2016 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,709 at $0.00 | filing |
| 23 Feb 2015filed 25 Feb 2015 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,190 at $0.00 | filing |
News
Biogen (NASDAQ:BIIB) Hits New 52-Week High Following Analyst UpgradeBIIB · dailypolitical.com · 14 Oct 2026Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?BIIB · insidermonkey.com · 13 Oct 2026Biogen (NASDAQ:BIIB) Stock Price Target Cut by Royal Bank Of CanadaBIIB · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name Steven H. Holtzman; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.